NO993948L - Anvendelse av aryl-cykloheksylamin-derivater mot CNS- forstyrrelser - Google Patents

Anvendelse av aryl-cykloheksylamin-derivater mot CNS- forstyrrelser

Info

Publication number
NO993948L
NO993948L NO993948A NO993948A NO993948L NO 993948 L NO993948 L NO 993948L NO 993948 A NO993948 A NO 993948A NO 993948 A NO993948 A NO 993948A NO 993948 L NO993948 L NO 993948L
Authority
NO
Norway
Prior art keywords
lower alkyl
aryl
cns disorders
ch2oh
tetrahydronaphthyl
Prior art date
Application number
NO993948A
Other languages
English (en)
Other versions
NO993948D0 (no
Inventor
Alexander Alanine
Bernd Buettelmann
Emmanuel Pinard
Rene Wyler
Marie-Paule Heitz Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO993948D0 publication Critical patent/NO993948D0/no
Publication of NO993948L publication Critical patent/NO993948L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelse av forbindelser med den generelle formel hvori Ar1 er fenyl, naftyl eller tetrahydronaftyl, eventuelt substituert med hydroksy, lavere alkoksy, nitro, amino eller metansulfonamid; er fenyl, naftyl eller tetrahydronaftyl, eventuelt substituert med lavere alkyl eller halogen; er C, CH, C(OH) eller N; er-CH2-, CH eller O; er -CH2-, -CH(CH3)- eller -C(CH3)2-; er hydrogen, lavere alkyl eller acetyl; er C=O eller -(CHR2)n-, hvori R2 er hydrogen, lavere alkyl eller hydroksy- lavere alkyl; er -(CH2)n., O, -CH(OH)(CH2)n-, -CH(CH2OH)(CH2)n-, -(CH2)nCH(OH)- eller -CH(CH2OH)-; ¿ kan være en binding; og n er 0-4 og farmasøytisk akseptable syreaddisjonssalter derav for fremstilling av medikamenter som representerer terapeutiske indikasjoner for NMDA-reseptor- subtype spesifikke blokkere.
NO993948A 1998-08-18 1999-08-17 Anvendelse av aryl-cykloheksylamin-derivater mot CNS- forstyrrelser NO993948L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98115484 1998-08-18

Publications (2)

Publication Number Publication Date
NO993948D0 NO993948D0 (no) 1999-08-17
NO993948L true NO993948L (no) 2000-02-21

Family

ID=8232474

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993948A NO993948L (no) 1998-08-18 1999-08-17 Anvendelse av aryl-cykloheksylamin-derivater mot CNS- forstyrrelser

Country Status (24)

Country Link
US (1) US6184236B1 (no)
JP (1) JP3455142B2 (no)
KR (1) KR100341194B1 (no)
CN (1) CN1141936C (no)
AR (1) AR021770A1 (no)
AT (1) ATE326219T1 (no)
AU (1) AU756408B2 (no)
BR (1) BR9903779A (no)
CA (1) CA2280455A1 (no)
DE (1) DE69931316D1 (no)
HR (1) HRP990256A2 (no)
HU (1) HUP9902737A3 (no)
ID (1) ID23107A (no)
IL (1) IL131399A0 (no)
MA (1) MA26677A1 (no)
MY (1) MY133133A (no)
NO (1) NO993948L (no)
NZ (1) NZ337243A (no)
PE (1) PE20000955A1 (no)
PL (1) PL334949A1 (no)
SG (1) SG82014A1 (no)
TR (1) TR199902015A2 (no)
YU (1) YU38699A (no)
ZA (1) ZA995212B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1292581B1 (en) * 2000-06-06 2005-08-10 Warner-Lambert Company LLC Bicyclic cyclohexylamines and their use as nmda receptor antagonists
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
DE10153345A1 (de) * 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinoxalin-2-on-Verbindungen und substituierte 4-Aryl- und 4-Heteroarylcyclohexan-Verbindungen
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
EP2170334B1 (en) * 2007-06-29 2021-03-17 Emory University Nmda receptor antagonists for neuroprotection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4032766A1 (de) 1990-10-16 1992-04-30 Basf Ag Phenylpiperidinoylamine und diese enthaltende arzneimittel
DE4117904A1 (de) 1991-05-31 1992-12-03 Basf Ag Substituierte n-phenylpiperidine
EP0503411B1 (de) 1991-03-14 1995-11-29 BASF Aktiengesellschaft Substituierte N-Phenylpiperidine und Arzneimittel daraus
AU715216B2 (en) * 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same

Also Published As

Publication number Publication date
TR199902015A3 (tr) 2000-03-21
KR100341194B1 (ko) 2002-06-20
HU9902737D0 (en) 1999-10-28
JP2000109429A (ja) 2000-04-18
MA26677A1 (fr) 2004-12-20
ID23107A (id) 2000-02-24
AR021770A1 (es) 2002-08-07
NZ337243A (en) 2000-12-22
HUP9902737A2 (hu) 2000-06-28
NO993948D0 (no) 1999-08-17
ATE326219T1 (de) 2006-06-15
CA2280455A1 (en) 2000-02-18
PE20000955A1 (es) 2000-09-28
AU756408B2 (en) 2003-01-09
YU38699A (sh) 2002-03-18
HRP990256A2 (en) 2000-04-30
CN1141936C (zh) 2004-03-17
MY133133A (en) 2007-10-31
CN1248439A (zh) 2000-03-29
IL131399A0 (en) 2001-01-28
BR9903779A (pt) 2000-09-19
DE69931316D1 (de) 2006-06-22
TR199902015A2 (xx) 2000-03-21
HUP9902737A3 (en) 2001-01-29
SG82014A1 (en) 2001-07-24
US6184236B1 (en) 2001-02-06
ZA995212B (en) 2000-02-18
PL334949A1 (en) 2000-02-28
AU4453799A (en) 2000-05-04
JP3455142B2 (ja) 2003-10-14
KR20000017343A (ko) 2000-03-25

Similar Documents

Publication Publication Date Title
BR9812046A (pt) Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto
PA8550201A1 (es) Analogos de prostaglandina
MY114679A (en) Aroyl-piperidine derivatives
SE8704747L (sv) Farmaceutisk komposition
EA200200446A1 (ru) НОВЫЕ α-АМИНОКИСЛОТНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ
GB2188234A (en) Obesity treating agents
SE0104334D0 (sv) Therapeutic agents
ATE235476T1 (de) Thiazolidindione derivate, ihre herstellung und verwendung
EA200300071A1 (ru) Терапевтический препарат для лечения невроза страха (тревоги) или депрессии и производные пиперазина
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
HUP0301458A2 (hu) Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása
NO993948L (no) Anvendelse av aryl-cykloheksylamin-derivater mot CNS- forstyrrelser
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
RU2208013C2 (ru) ПРОИЗВОДНЫЕ 8-ЗАМЕЩЕННОГО-9H-1,3-ДИОКСОЛ/4,5-h//2,3/БЕНЗОДИАЗЕПИНА, ЯВЛЯЮЩИЕСЯ ИНГИБИТОРАМИ AMPA/КАИНАТНОГО РЕЦЕПТОРА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ
EP0982026A3 (en) Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
KR940009179A (ko) 벤조푸란 유도체, 그의 제조 방법, 그를 함유한 제약조성물 및 그의 의약으로서의 용도
DK0871626T3 (da) Triazoloner som apolipoprotein-B syntheseinhibitorer
TR199801774T2 (xx) 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�.
PL378343A1 (pl) Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny
DE3470883D1 (en) Tetrahydroisoxazolo(4,5-c)pyridine derivatives and preparation thereof
HUP0402600A2 (hu) D-prolin származékok és a vegyületeket tartalmazó gyógyszerkészítmények
CZ30097A3 (en) Novel streptogramin derivatives, process of their preparation and pharmaceutical composition containing thereof
ECSP993105A (es) El uso de los derivados de aril- ciclohexilamina contra transtornos del sistema nervioso central
AR030410A1 (es) Derivados de 2-fenilpiran-4-ona, proceso para obtener dichos derivados, composiciones farmaceuticas que comprenden los derivados mencionados y el uso de los mismos en la manufactura de medicamentos
KR830000903A (ko) 고혈압과 장장애를 억제하는 방법과 조성물